Drug
Nelitolimod clinical trials
Also written SD-101.
Includes 4 studies of Nelitolimod sodium.
- studies test it
- 25
- open now
- 4
- in phase 3
- 4
- first study started
- 2008
Keep track of what changes. Save the nelitolimod studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
- SD-101
- 16
Combined with it in one product
Studies by the year they started
25 studies that test it; most in 2014 (4)
| Year | Studies |
|---|---|
| 2008 | 2 |
| 2010 | 1 |
| 2012 | 1 |
| 2014 | 4 |
| 2015 | 3 |
| 2016 | 2 |
| 2017 | 1 |
| 2018 | 2 |
| 2019 | 2 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 1 |
| 2025 | 2 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 16
- Phase 2
- 10
- Phase 3
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 14 · Other 11
Scioderm, Inc. (4) · Dynavax Technologies Corporation (4) · TriSalus Life Sciences, Inc. (3) · Robert Lowsky (3) · Ronald Levy (2) · University of California, Davis (2) · Paradigm Therapeutics (2) · University of California, San Diego (1)
Often tested with
Tested in the same studies.
Durvalumab (2) · Pembrolizumab (2) · BMS-986178 (2) · Tremelimumab (1) · Leuprolide (1) · Abiraterone Acetate (1) · Abiraterone (1) · Prednisone (1)
Studies
Open first, then newest update. How each study uses nelitolimod is read from its arms, and is right about nine times in ten.
Testing it · 25
- Efficacy and Safety Study to Evaluate SD-101 in Epidermolysis BullosaRecruitingPhase 3Paradigm TherapeuticsNCT07482787Written as SD-101 Dermal Cream (6%)
- An Open Label Extension Safety Study to Evaluate SD-101 in Epidermolysis BullosaNot yet recruitingPhase 3Paradigm TherapeuticsNCT07482813Written as SD-101 Dermal Cream (6%)
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerRecruitingPhase 2QuantumLeap Healthcare CollaborativeNCT01042379Written as SD-101 + Pembrolizumab
- INFINITIVE: ImmuNotherapy For PatIeNts wIth colorecTal LIVer MEtastasesRecruitingEarly Phase 1Northwell HealthNCT07172282Written as Nelitolimod
- Cryoablation and Arterial Infusion of SD-101 in Combination With Durvalumab and TremelimumabActive, not recruitingPhase 1University of California, San DiegoNCT06710223Written as SD-101
- Pembrolizumab +/- SD-101 in Hormone-Naïve Oligometastatic Prostate Cancer With RT and iADTCompletedPhase 2David OhNCT03007732Written as SD-101
- Pressure Enabled Delivery of SD-101 With Checkpoint Blockade for Primary Liver TumorsTerminatedPhase 1/2TriSalus Life Sciences, Inc.NCT05220722Written as SD-101
- Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal MelanomaTerminatedPhase 1TriSalus Life Sciences, Inc.NCT04935229Written as SD-101
- Pressure Enabled Intrapancreatic Delivery of SD-101 With Checkpoint Blockade for Locally Advanced Pancreatic AdenocarcinomaActive, not recruitingPhase 1TriSalus Life Sciences, Inc.NCT05607953Written as SD-101
- TLR9 Agonist SD-101, Anti-OX40 Antibody BMS 986178, and Radiation Therapy in Treating Patients With Low-Grade B-Cell Non-Hodgkin LymphomasCompletedPhase 1Ronald LevyNCT03410901Written as TLR9 Agonist SD-101
- TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular LymphomaCompletedPhase 1/2Robert LowskyNCT02927964Written as TLR9 Agonist SD-101
- SD-101 and BMS-986178 in Treating Patients With Advanced or Metastatic Solid MalignanciesCompletedPhase 1Ronald LevyNCT03831295Written as TLR9 Agonist SD-101
- SD-101, Nivolumab, and Radiation Therapy in Treating Patients With Chemotherapy-Refractory Metastatic Pancreatic CancerCompletedPhase 1University of California, DavisNCT04050085Written as TLR9 Agonist SD-101
- UCDCC#271: Phase I/II Trial of Epacadostat, Intralesional SD101, Radiotherapy in Patients With LymphomaCompletedPhase 1/2University of California, DavisNCT03322384Written as SD-101
- A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaTerminatedPhase 1/2Dynavax Technologies CorporationNCT02521870Written as SD-101(1)
- Study of SD-101 in Combination With Localized Low-dose Radiation in Patients With Untreated Low-grade B-cell LymphomaTerminatedPhase 1/2Dynavax Technologies CorporationNCT02266147Written as SD-101
- ESSENCE Study: Efficacy and Safety of SD-101 Cream in Participants With Epidermolysis BullosaCompletedPhase 3Scioderm, Inc.NCT02384460Written as SD-101-6.0 cream
- Study of Effectiveness and Safety of SD-101 in Participants With Epidermolysis BullosaCompletedPhase 2Scioderm, Inc.NCT02014376Written as SD-101 dermal cream (3%)
- A Phase I/II Study of Intratumoral Injection of SD-101CompletedPhase 1/2Robert LowskyNCT02254772Written as SD-101
- Open-Label Extension Study to Evaluate the Safety of SD-101 Cream in Participants With Epidermolysis BullosaTerminatedPhase 2Scioderm, Inc.NCT02090283Written as SD-101 dermal cream (6%)
Codes
What other systems call nelitolimod · ClinicalTrials.gg INT016748
- UNII (FDA) H5RNU52ZKKNELITOLIMODOne source FDA
- NCI Thesaurus C74084NelitolimodOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | H5RNU52ZKK | NELITOLIMOD | One source FDA |
| NCI Thesaurus | C74084 | Nelitolimod | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.